Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Open-label studie för att utvärdera säkerheten och effektiviteten av CABA-201 hos personer med aktiv idiopatisk inflammatorisk myopati

12 november 2026 uppdaterad av: Cabaletta Bio

En öppen fas 1/2-studie för att utvärdera säkerheten och effektiviteten av autologa CD19-specifika chimära antigenreceptor-T-celler (CABA-201) hos patienter med aktiv idiopatisk inflammatorisk myopati

RESET-Myositis: Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects with Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy

Studieöversikt

Detaljerad beskrivning

Idiopathic inflammatory myopathies (IIMs, or myositis) are a group of rare autoimmune diseases characterized by inflammation and muscle weakness. Though the cause of IIM is not well understood, some subtypes of IIM, including dermatomyositis (DM), anti-synthetase syndrome (ASyS), immune-mediated necrotizing myopathy (IMNM), and juvenile idiopathic inflammatory myopathy (JIIM), are thought to involve B cells that cause the body to attack different tissues in the body. This study is being conducted to evaluate the safety and efficacy of an investigational cell therapy, CABA-201, that can be given to patients with DM, ASyS, IMNM, or JIIM who have active disease. A single dose of CABA-201 in combination with cyclophosphamide (CY) and fludarabine (FLU) will be evaluated.

Studietyp

Interventionell

Inskrivning (Beräknad)

74

Fas

  • Fas 2
  • Fas 3

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

    • California
      • Orange, California, Förenta staterna, 92868
        • Rekrytering
        • University of California Irvine - Accepting Adult Patients
        • Huvudutredare:
          • Tahseen Mozaffar, MD
        • Kontakt:
      • San Francisco, California, Förenta staterna, 94158
        • Rekrytering
        • University of California, San Francisco Benioff Children's Hospital - Accepting Young Adult and Juvenile Patients
        • Kontakt:
        • Huvudutredare:
          • Susan Kim, MD, MMSc
    • Colorado
      • Aurora, Colorado, Förenta staterna, 80046
        • Rekrytering
        • Children's Hospital Colorado - Accepting Juvenile Patients
        • Huvudutredare:
          • Dr. Kentaro Yomogida, MD
        • Kontakt:
    • Florida
      • Jacksonville, Florida, Förenta staterna, 32224
        • Rekrytering
        • Mayo Clinic Florida - Accepting Adult Patients
        • Kontakt:
      • St. Petersburg, Florida, Förenta staterna, 33701
        • Rekrytering
        • Johns Hopkins All Children's Hospital - Accepting Juvenile Patients
        • Huvudutredare:
          • Natalie Booth, DO
        • Kontakt:
    • Georgia
      • Atlanta, Georgia, Förenta staterna, 30032
        • Rekrytering
        • Emory University - Accepting Adult Patients
        • Kontakt:
        • Huvudutredare:
          • Prateek Chandrashekar Gandiga, MD, FACP
      • Atlanta, Georgia, Förenta staterna, 30029
        • Rekrytering
        • Children's Healthcare of Atlanta - Accepting Juvenile Patients
        • Huvudutredare:
          • Shanmuganathan Chandrakasan, MD
        • Kontakt:
    • Illinois
      • Chicago, Illinois, Förenta staterna, 60611
        • Rekrytering
        • Northwestern Memorial Hospital - Accepting Adult Patients
        • Huvudutredare:
          • Dr. George Georges, MD
        • Kontakt:
      • Chicago, Illinois, Förenta staterna, 60637
      • Chicago, Illinois, Förenta staterna, 60611
        • Rekrytering
        • Ann & Robert H. Lurie Children's Hospital of Chicago - Accepting Young Adult and Juvenile Patients
        • Kontakt:
        • Huvudutredare:
          • Pooja N. Patel, DO
    • Kansas
      • Kansas City, Kansas, Förenta staterna, 66160
        • Rekrytering
        • University of Kansas Medical Center - Accepting Adult Patients
        • Kontakt:
    • Maryland
      • Bethesda, Maryland, Förenta staterna, 20892
        • Rekrytering
        • National Institutes of Health - Accepting Adult and Juvenile Patients
        • Kontakt:
        • Huvudutredare:
          • Andrew Mammen, M.D., Ph.D.
    • Massachusetts
      • Boston, Massachusetts, Förenta staterna, 02115
        • Rekrytering
        • Boston Children's Hospital - Accepting Young Adults and Juvenile Patients
        • Huvudutredare:
          • Susan Prockop, MD
        • Kontakt:
    • Michigan
      • Ann Arbor, Michigan, Förenta staterna, 48105
        • Rekrytering
        • University of Michigan - Accepting Young Adult and Juvenile Patients
        • Kontakt:
        • Huvudutredare:
          • Dr. Jennifer Agrusa, MD
    • Minnesota
      • Rochester, Minnesota, Förenta staterna, 55902
        • Rekrytering
        • Mayo Clinic - Accepting Adult Patients
        • Kontakt:
    • New York
      • New York, New York, Förenta staterna, 10021
        • Rekrytering
        • Hospital for Special Surgery - Accepting Adult and Juvenile Patients
        • Kontakt:
        • Huvudutredare:
          • David R. Fernandez, MD, PhD
      • New York, New York, Förenta staterna, 10021
        • Rekrytering
        • Memorial Sloan Kettering Cancer Center - Accepting Adult and Juvenile Patients
        • Huvudutredare:
          • Jae Park, MD
        • Kontakt:
      • The Bronx, New York, Förenta staterna, 10467
        • Rekrytering
        • Children's Hospital at Montefiore - Accepting Young Adult and Juvenile Patients
        • Kontakt:
        • Huvudutredare:
          • Dr. Dawn Wahezi, MD, MS
    • North Carolina
      • Chapel Hill, North Carolina, Förenta staterna, 27599
        • Rekrytering
        • University of North Carolina at Chapel Hill - Accepting Adult Patients
        • Huvudutredare:
          • Saira Sheikh, MD
        • Kontakt:
      • Durham, North Carolina, Förenta staterna, 27710
        • Rekrytering
        • Duke University Medical Center - Accepting Young Adults and Juvenile Patients
        • Huvudutredare:
          • Kaveh Ardalan, MD, MS
        • Kontakt:
    • Oregon
      • Portland, Oregon, Förenta staterna, 97239
        • Rekrytering
        • Oregon Health & Science University - Accepting Adult Patients
        • Kontakt:
    • Pennsylvania
      • Philadelphia, Pennsylvania, Förenta staterna, 19104
        • Rekrytering
        • Children's Hospital of Philadelphia - Accepting Young Adult and Juvenile Patients
        • Kontakt:
        • Huvudutredare:
          • Dr. Caitlin Elgarten, MD, MSCE
      • Pittsburgh, Pennsylvania, Förenta staterna, 15261
        • Rekrytering
        • UPMC Arthritis and Autoimmunity Center - Accepting Adult Patients
        • Kontakt:
        • Huvudutredare:
          • Jeremy Tilstra, MD
      • Pittsburgh, Pennsylvania, Förenta staterna, 15224
        • Rekrytering
        • UPMC Children's Hospital of Pittsburgh - Accepting Juvenile Patients
        • Kontakt:
        • Huvudutredare:
          • Kathryn Torok, MD
    • Tennessee
      • Nashville, Tennessee, Förenta staterna, 37232
        • Rekrytering
        • Vanderbilt University Medical Center - Accepting Adult Patients
        • Kontakt:
    • Texas
      • Dallas, Texas, Förenta staterna, 75390
        • Rekrytering
        • University of Texas Southwestern Medical Center - Accepting Juvenile Patients
        • Huvudutredare:
          • Samuel John, MD
        • Kontakt:
      • Houston, Texas, Förenta staterna, 77030
        • Rekrytering
        • Houston Methodist Hospital - Accepting Adult Patients
        • Kontakt:
      • Houston, Texas, Förenta staterna, 77030
        • Rekrytering
        • University of Texas MD Anderson Cancer Center - Accepting Adult Patients
        • Huvudutredare:
          • Huifang (Linda) Lu, MD
        • Kontakt:
    • Utah
      • Salt Lake City, Utah, Förenta staterna, 84113
        • Rekrytering
        • Primary Children's Hospital/University of Utah - Accepting Juvenile Patients
        • Kontakt:
        • Huvudutredare:
          • Aimee Ogden Hersh, MD
    • Washington
      • Seattle, Washington, Förenta staterna, 98105
        • Rekrytering
        • Seattle Children's Research Institute - Accepting Juvenile Patients
        • Kontakt:
        • Huvudutredare:
          • Dr. Susan Shenoi, MD, MS
    • Wisconsin
      • Milwaukee, Wisconsin, Förenta staterna, 53226
        • Har inte rekryterat ännu
        • Children's Wisconsin Pediatric Rheumatology -Accepting Young Adult and Juvenile Patients
        • Huvudutredare:
          • Sara Sabbagh, DO
        • Kontakt:
          • Erin Hammelev - Research Coordinator
          • Telefonnummer: 414-337-7064
          • E-post: ehammele@mcw.edu
      • Roma, Italien, 00165
        • Rekrytering
        • Ospedale Pediatrico Bambino Gesù - Accepting Young Adult and Juvenile Patients
        • Kontakt:
        • Huvudutredare:
          • Professor Franco Locatelli
      • London, Storbritannien, WC1N 3BG
        • Rekrytering
        • University College London Hospitals NHS Foundation Trust - Accepting Adult Patients
        • Kontakt:
        • Huvudutredare:
          • Dr. Pedro Machado, FRCP, PhD
      • London, Storbritannien, SE5 9RS
        • Rekrytering
        • Kings College Hospital NHS Foundation Trust - Accepting Adult Patients
        • Kontakt:
        • Huvudutredare:
          • Patrick Gordon, PhD, FRCP, MBBS
      • London, Storbritannien, WC1N 3JH
        • Rekrytering
        • Great Ormond Street Hospital for Children NHS Foundation Trust - Accepting Juvenile Patients
        • Kontakt:
        • Huvudutredare:
          • Professor Despina Eleftheriou
      • Manchester, Storbritannien, M13 9WL
        • Rekrytering
        • Manchester Royal Infirmary - Accepting Adult Patients
        • Kontakt:
        • Huvudutredare:
          • Eleni Tholouli, MD, PhD, MRCP(UK), FRCPath
      • Salford, Storbritannien, M6 8HD
        • Rekrytering
        • Salford Royal Hospital - Accepting Adult Patients
        • Kontakt:
        • Huvudutredare:
          • Hector Chinoy, PhD, FRCP, MSc, BMBS, BMedSci
      • Göttingen, Tyskland, 37075
        • Har inte rekryterat ännu
        • Universitätsmedizin Göttingen - Accepting Adult Patients
        • Kontakt:
        • Huvudutredare:
          • Dr. Jana Zschüntzsch

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

6 år till 75 år (Barn, Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Adult Cohorts

Inclusion Criteria:

  • Age ≥18 and ≤75
  • A clinical diagnosis of IIM, based on the 2017 The European League Against Rheumatism/American College of Rheumatology classification criteria
  • Diagnosis of DM, ASyS, or IMNM
  • Evidence of active disease, despite prior or current treatment with standard of care treatments, as defined by the presence of elevated creatine kinase (CK), DM rash, or active disease on muscle biopsy, magnetic resonance imaging (MRI), or electromyography
  • Presence of muscle weakness

Other protocol-defined criteria apply.

Exclusion Criteria:

  • Contraindication to leukapheresis
  • History of anaphylactic or severe systemic reaction to fludarabine, cyclophosphamide or any of their metabolites
  • Active infection requiring medical intervention at screening
  • Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, psychiatric, cardiac, neurological, or cerebral disease, including severe and uncontrolled infections, such as sepsis and opportunistic infections
  • Concomitant medical conditions that, in the opinion of the investigator, might place the subject at unacceptable risk for participation in this study, interfere with the assessment of the effects or safety of the investigational product or with the study procedures
  • Significant lung or cardiac impairment
  • Previous CAR T cell therapy
  • Prior solid organ (heart, liver, kidney, lung) transplant or hematopoietic cell transplant

Other protocol-defined criteria apply.

Juvenile Cohort

Inclusion Criteria:

  • Age ≥6 and ≤17 years at enrollment
  • A clinical diagnosis of IIM, based on the 2017 The European League Against Rheumatism/American College of Rheumatology classification criteria
  • Evidence of active disease, despite prior or current treatment with standard of care treatments, as defined by the presence of elevated muscle enzymes, DM rash, or active disease on muscle biopsy, magnetic resonance imaging (MRI), or electromyography

Other protocol-defined criteria apply.

Exclusion Criteria:

  • Contraindication to leukapheresis
  • History of anaphylactic or severe systemic reaction to fludarabine, cyclophosphamide or any of their metabolites
  • Active infection requiring medical intervention at screening
  • Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, psychiatric, cardiac, neurological, or cerebral disease, including severe and uncontrolled infections, such as sepsis and opportunistic infections.
  • Concomitant medical conditions that, in the opinion of the investigator, might place the subject at unacceptable risk for participation in this study, interfere with the assessment of the effects or safety of the investigational product or with the study procedures
  • Significant lung or cardiac impairment
  • Previous CAR T cell therapy
  • Prior solid organ (heart, liver, kidney, lung) transplant or hematopoietic cell transplant

Other protocol-defined criteria apply.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Icke-randomiserad
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: CABA-201 Phase 1/2

DM Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with DM.

ASyS Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with ASyS.

IMNM Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with IMNM.

JIIM Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with JIIM.

Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide

Andra namn:
  • Rese
  • Resecabtagene autoleucel
Experimentell: CABA-201 Phase 2b - Sub-study 1

Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with DM and ASyS.

Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide

Andra namn:
  • Rese
  • Resecabtagene autoleucel
Experimentell: CABA-201 Phase 2b - Sub-study 2

Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with IMNM.

Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide

Andra namn:
  • Rese
  • Resecabtagene autoleucel

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Phase 1/2: Incidence and severity of adverse events (AEs)
Tidsram: Up to 28 days after CABA-201 infusion

Incidence and severity of AEs

Up to 28 days after CABA-201 infusion
Phase 2b Sub-study 1: Proportion of DM & ASyS subjects achieving at least a moderate Total Improvement Score (TIS) without any immunomodulatory medications and no or low dose of steroids
Tidsram: Within 16 weeks

≥40 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement

Within 16 weeks
Phase 2b Sub-study 2: Proportion of subjects with IMNM achieving at least a minimal TIS without any immunomodulatory medications and no or low dose of steroids
Tidsram: Within 24 weeks

≥20 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement

Within 24 weeks

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Incidence of adverse events and laboratory abnormalities
Tidsram: Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)

Incidence and severity of AEs, including changes in laboratory values and vital signs

Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
Pharmacodynamics (PD)
Tidsram: Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)

Levels of B cells in the blood

Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
Pharmacokinetics (PK)
Tidsram: Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)

Levels of CABA-201-positive T cells in the blood

Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
Change in disease-related biomarkers of muscle inflammation
Tidsram: Up to 156 weeks (Phase 1/2)

Levels of muscle enzymes (CK, LDH, AST, ALT, and aldolase) in serum

Up to 156 weeks (Phase 1/2)
Change in autoantibody-related biomarkers
Tidsram: Up to 156 weeks (Phase 1/2)

Levels of autoantibodies from the Myositis-Specific Autoantibody Panel (e.g., MDA-5, Jo-1, and HMGCR) in the serum

Up to 156 weeks (Phase 1/2)
Proportion of DM subjects achieving at least a moderate TIS without any immunomodulatory medications and no or low dose of steroids
Tidsram: Week 16 (Sub-study 1)

≥40 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement

Week 16 (Sub-study 1)
Mean change from baseline on the MMT-8 in subjects with DM and ASyS without any immunomodulatory medications and no or low dose of steroids
Tidsram: Week 16 (Sub-study 1)

MMT-8 measures muscle strength on a scale ranging from 0 to 150 points, where higher scores reflect greater muscle strength

Week 16 (Sub-study 1)
Proportion of DM and ASyS subjects achieving a major TIS response without any immunomodulatory medications and no or low dose of steroids
Tidsram: Week 16 (Sub-study 1)

≥60 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement

Week 16 (Sub-study 1)
Proportion of subjects with DM & ASyS achieving moderate TIS without any immunomodulatory medications on no or low dose of steroids
Tidsram: Week 52 (Sub-study 1)

≥40 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement

Week 52 (Sub-study 1)
Proportion of subjects with DM achieving moderate TIS without any immunomodulatory medications on no or low dose of steroids
Tidsram: Week 52 (Sub-study 1)

≥40 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement

Week 52 (Sub-study 1)
Mean change from baseline on the MMT-8 in subjects with IMNM without any immunomodulatory medications and no or low dose of steroids
Tidsram: Week 24 (Sub-study 2)

MMT-8 measures muscle strength on a scale ranging from 0 to 150 points, where higher scores reflect greater muscle strength

Week 24 (Sub-study 2)
Proportion of subjects with IMNM achieving at least minimal TIS response without immunomodulatory medications and no or low dose of steroids
Tidsram: Week 52 (Sub-study 2)

≥20 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement

Week 52 (Sub-study 2)

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Utredare

  • Studiestol: Medical Director, Cabaletta Bio

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

20 december 2023

Primärt slutförande (Beräknad)

1 juli 2028

Avslutad studie (Beräknad)

1 juli 2028

Studieregistreringsdatum

Först inskickad

16 november 2023

Först inskickad som uppfyllde QC-kriterierna

30 november 2023

Första postat (Faktisk)

4 december 2023

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

13 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

12 november 2026

Senast verifierad

1 november 2026

Mer information

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera